BCL2L11 and cancer: We speculate the binding interface between CTSs of Bim and Puma and anti-apoptotic proteins could be potential drug targets as disrupting these binding sites would enable BH3-mimetics to efficiently displace Bim and Puma from the anti-apoptotic proteins and activate Bax or Bak to kill cancer cells.